Margaret A.WinkerMD, Deputy EditorIndividualAuthorPhil B.FontanarosaMD, Interim CoeditorIndividualAuthor
Copyright 1999 American Medical Association.
All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.1999
To the Editor: Simulation modeling is a
powerful and appropriate tool for examining the possible impact of
screening for type 2 diabetes, and we agree with the conclusion of the
CDC Diabetes Cost-Effectiveness Study Group that "the selection of
appropriate target populations for screening
should consider factors in addition to the prevalence of
diabetes."1 However, we are concerned that their model
disregards some of the important factors that influence outcomes.
Goyder E, Irwig L. Screening for Type 2 Diabetes. JAMA. 1999;281(21):1986-1988. doi:10-1001/pubs.JAMA-ISSN-0098-7484-281-21-jbk0602